These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 30194034)

  • 1. Biomarker Clinical Trials in Lung Cancer: Design, Logistics, Challenges, and Practical Considerations.
    Le-Rademacher J; Dahlberg S; Lee JJ; Adjei AA; Mandrekar SJ
    J Thorac Oncol; 2018 Nov; 13(11):1625-1637. PubMed ID: 30194034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New clinical trial designs in the era of precision medicine: An overview of definitions, strengths, weaknesses, and current use in oncology.
    Janiaud P; Serghiou S; Ioannidis JPA
    Cancer Treat Rev; 2019 Feb; 73():20-30. PubMed ID: 30572165
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Trials in Non-Small Cell Lung Cancer with Biomarker-Driven Treatment Allocation: Ready or Not, Here We Come.
    Garon EB; Abarca PA; Strunck JL; Nameth D; Neumann C; Wolf B; Kim KY; Marx C; Elashoff RM
    Crit Rev Oncog; 2015; 20(5-6):339-47. PubMed ID: 27279233
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biomarker-driven early clinical trials in oncology: a paradigm shift in drug development.
    Tan DS; Thomas GV; Garrett MD; Banerji U; de Bono JS; Kaye SB; Workman P
    Cancer J; 2009; 15(5):406-20. PubMed ID: 19826361
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biomarker-Driven Oncology Clinical Trials: Key Design Elements, Types, Features, and Practical Considerations.
    Hu C; Dignam JJ
    JCO Precis Oncol; 2019; 3():. PubMed ID: 32923854
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reinventing clinical trials: a review of innovative biomarker trial designs in cancer therapies.
    Lin JA; He P
    Br Med Bull; 2015 Jun; 114(1):17-27. PubMed ID: 25921239
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Standard of care in immunotherapy trials: Challenges and considerations.
    Rivalland G; Scott AM; John T
    Hum Vaccin Immunother; 2017 Sep; 13(9):2164-2178. PubMed ID: 28267397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biomarker driven population enrichment for adaptive oncology trials with time to event endpoints.
    Mehta C; Schäfer H; Daniel H; Irle S
    Stat Med; 2014 Nov; 33(26):4515-31. PubMed ID: 25130879
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current Landscape of Targeted Therapy in Lung Cancer.
    Mayekar MK; Bivona TG
    Clin Pharmacol Ther; 2017 Nov; 102(5):757-764. PubMed ID: 28786099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Innovative Clinical Trials: The LUNG-MAP Study.
    Steuer CE; Papadimitrakopoulou V; Herbst RS; Redman MW; Hirsch FR; Mack PC; Ramalingam SS; Gandara DR
    Clin Pharmacol Ther; 2015 May; 97(5):488-91. PubMed ID: 25676724
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An update on biomarkers for kinase inhibitor response in non-small-cell lung cancer.
    Ku BM; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
    Expert Rev Mol Diagn; 2017 Oct; 17(10):933-942. PubMed ID: 28838271
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lung cancer in the era of precision medicine.
    Politi K; Herbst RS
    Clin Cancer Res; 2015 May; 21(10):2213-20. PubMed ID: 25979927
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Methodology of clinical trials in lung cancer.
    Menis J; Besse B; Lacombe D
    Chin Clin Oncol; 2015 Dec; 4(4):44. PubMed ID: 26730756
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An overview of the design and conduct of the BATTLE trials.
    Liu S; Lee JJ
    Chin Clin Oncol; 2015 Sep; 4(3):33. PubMed ID: 26408300
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Statistical controversies in clinical research: basket trials, umbrella trials, and other master protocols: a review and examples.
    Renfro LA; Sargent DJ
    Ann Oncol; 2017 Jan; 28(1):34-43. PubMed ID: 28177494
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advancing cancer drug development through precision medicine and innovative designs.
    Zhang W; Wang J; Menon S
    J Biopharm Stat; 2018; 28(2):229-244. PubMed ID: 29173004
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLC.
    Camidge DR; Doebele RC; Kerr KM
    Nat Rev Clin Oncol; 2019 Jun; 16(6):341-355. PubMed ID: 30718843
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Review of ongoing clinical trials in non-small cell lung cancer: a status report for 2009 from the ClinicalTrials.gov website.
    Subramanian J; Madadi AR; Dandona M; Williams K; Morgensztern D; Govindan R
    J Thorac Oncol; 2010 Aug; 5(8):1116-9. PubMed ID: 20592626
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early Phase Clinical Trial Designs - State of Play and Adapting for the Future.
    Harrington JA; Hernandez-Guerrero TC; Basu B
    Clin Oncol (R Coll Radiol); 2017 Dec; 29(12):770-777. PubMed ID: 29108786
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Innovation in oncology clinical trial design.
    Verweij J; Hendriks HR; Zwierzina H;
    Cancer Treat Rev; 2019 Mar; 74():15-20. PubMed ID: 30665053
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.